A phase II study of platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer
Latest Information Update: 11 Sep 2023
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Etoposide (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHEST RT; TROG 20.01 CHEST RT
- 24 Jul 2023 Planned End Date changed from 31 Jul 2026 to 28 Feb 2028.
- 24 Jul 2023 Planned primary completion date changed from 31 Jul 2023 to 30 Sep 2027.
- 14 Jun 2023 Status changed from not yet recruiting to recruiting.